Notice - Prescription Drug List (PDL): Lovastatin

December 5, 2014
Our file number: 14-115026-541

The purpose of this Notice of Amendment is to announce the revised listing for lovastatin on the Prescription Drug List (PDL). As stated in the Notice of Intent to Amend, posted June 4, 2014, the revision will allow lovastatin to be marketed as a nonprescription product when sold in an oral dosage form that provides no more than 1 milligram (mg) per daily dose. Only the Human part of the PDL has been revised. The wording of the revised listing is:

• Drugs containing any of the following: Lovastatin
• Including (but not limited to):
  • Qualifier: except in oral dosage form that provides 1 mg or less per daily dose
  • Effective Date: date of this Notice

Should you have any questions on this update to the Prescription Drug List, please contact:

• Prescription Drug Status Committee
  Health Canada
  Holland Cross, Tower B, 2^nd Floor
  1600 Scott Street
  Address Locator 3102C3
  Ottawa, Ontario
  K1A 0K9
• Email: drug_prescription_status-statut_d'ordonnance_des_drogues@hc-sc.gc.ca
  Phone: 613-957-1058
  Fax: 613-941-5035